H.C. Wainwright analyst Yi Chen assumed coverage of Lipocine (LPCN) with a Buy rating and $8 price target Lipocine’s first commercialized product, Tlando, an oral treatment indicated for testosterone replacement therapy, was approved by the FDA in 2022 and its current lead pipeline candidate is LPCN 1154, which is a rapid onset, oral formulation of the neuroactive steroid brexanolone for the treatment of postpartum depression, the analyst tells investors. If successfully developed, LPCN 1154 could “bring significant value to the company,” says the analyst, who notes that the firm’s current valuation is primarily based on market prospects for LPCN 1154.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue